Technology evaluation: EPI-2010, EpiGenesis.
EpiGenesis, in collaboration with Taisho and Chiesi, is developing EPI-2010, a 21-mer phosphorothioate respirable antisense oligonucleotide (RASON) that blocks the synthesis of the adenosine A1 receptor, for the potential treatment of asthma.